
It isn’t too often that you find a seriously undervalued company that’s just signed an acquisition for a company in a booming sector. So if you haven’t yet heard about Victory Square Technologies, you might want to read on.
Victory Square Technologies (VST) is a publicly-traded company based out of Vancouver that offers investors early-stage access to “the next unicorns before they’re unicorns”.
The company’s diverse portfolio of mythical creatures that it pairs investors with are all in the disruptive sector of tech—and range from digital health to gaming, blockchain, VR, AR, cyber security, and cloud computing.
The good news is that VST just made a big move to acquire Hydreight—an on-demand mobile health, pharmaceutical, and wellness service provider in the US.
We all know how successful telehealth technology has been recently due to COVID, and thankfully Hydreight has tapped into this niche. Its app allows customers to book private telehealth sessions from the convenience of their mobile phone and is both HIPA compliant and a certified e-script and telemedicine provider in the US.
The company also offers a wide array of health services including IV drip, Botox, COVID testing, and other medical treatments across 50 states in the US.
COVID is far from over and even when it is, it is highly likely people will continue to opt for telehealth appointments over in-person doctor appointments. It’s safe to say that the telehealth industry is here to stay.
Customers can book anytime, anywhere, and the app’s convenience and user-friendliness are two key factors in determining it a successful and disruptive technology. VST is also well connected, with key relationships with small vendors in medicine and many pharmacies.
Shafin Diamond Tejnai, CEO of VST, is confident with the choice to acquire Hydreight. “It is particularly impressive to see Hydreight not only make medicine and medical procedures available to ‘your door’ in the click of a button, but to also make it completely end to end turnkey for healthcare professionals. The technology itself is merely the vessel, it is the bolstering of that technology with compliance, insurance, and legal security that makes Hydreight a creator of an entirely new space,” Tenjai says.
Hydreight has announced revenue of $1 million CAD, an additional million to VST’s revenue. Further, on January 11, its subsidiary Victory Square Health received approval for its 15-minute COVID rapid test for distribution sale and usage in Brazil. The test has 96.6% sensitivity and can confirm whether someone is currently infected with COVID or has been in the past.
On January 13, VST also announced a share buyback program for 2021, stating that it believes the market price of its common shares from time to time may not reflect their underlying value.
An important takeaway from this is to realize that VST has the capital to do this. The shares they buy back now could be reissued at a higher share price for future financings (an overall net benefit for VST and its shareholders).
In terms of valuation, the company is very undervalued and is highly likely to triple from here just based on valuation alone. And that’s without the premiums to be paid.
If you’re looking for a solid, safe, high growth play, VST might be a company you want to look into.